How Will Merck & Co., Inc. (MRK)’s Earnings Fare Tomorrow?

In Merck’s earnings, watch for the company to expand on its victory yesterday in a jury trial regarding its Fosamax treatment for osteoporosis. With thousands of similar lawsuits in the works, the case was the first to reach a jury verdict, and good news could help the company clamp down on what could otherwise be huge potential liability.

The article How Will Merck’s Earnings Fare Tomorrow? originally appeared on Fool.com is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.